Clinical Trial Update: Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

A Phase I trial is evaluating the integration of HLA-haploidentical anti-CD19 CAR-T cells with post-transplant cyclophosphamide-based haploidentical hematopoiet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Hematologic Neoplasms

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• HLA-haploidentical anti-CD19 CAR-T cells (CD19-targeted CAR-T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Status: RECRUITING